What is the appropriate dosage of ipamorelin and CJC-1295 for increasing height?

Ipamorelin/CJC-1295 Dosage for Growth Hormone Release to Increase Height

There is no FDA-approved or medically recommended dosage of ipamorelin and CJC-1295 for increasing height, as these peptides are not approved for clinical use in height enhancement and may pose significant health risks. 1

Medical Context and Evidence

• Growth hormone therapy for height enhancement is only recommended in specific medical conditions like chronic kidney disease (CKD), and uses approved recombinant human growth hormone at doses of 0.045-0.05 mg/kg/day, not peptides like ipamorelin or CJC-1295 1
• The Endocrine Society recommends that growth hormone replacement should only be considered in patients with documented GH deficiency, particularly in children who have not completed linear growth 2
• Clinical studies of CJC-1295 in healthy adults used doses of 30-60 μg/kg for research purposes only, not for height enhancement, and noted potential cumulative effects with multiple dosing 3
• Animal studies of ipamorelin used doses of 18-450 μg/day administered three times daily in rats, which cannot be directly translated to human dosing 4

Safety Concerns

• Potential adverse effects of growth hormone secretagogues include:
  • Intracranial hypertension, which can lead to papilledema and vision loss 1
  • Accelerated bone maturation, which could paradoxically reduce final adult height 1
  • Metabolic effects including potential glucose intolerance 1
  • Unknown long-term safety profile as these compounds lack FDA approval 5, 3

Important Clinical Considerations

• Height growth is a complex process influenced by:

  • Genetic target height based on parental height 1
  • Bone age and epiphyseal plate status - once growth plates close, no further height increase is possible 1
  • Pubertal stage - growth velocity naturally increases during puberty and then ceases 1

• Medical evaluation for short stature should include:

  • Assessment of growth velocity over at least 6 months 1
  • Radiographic evaluation of bone age to determine growth potential 1
  • Endocrine evaluation including thyroid function and IGF-1 levels 1

Medical Alternatives

• For children with documented growth hormone deficiency or other approved indications, recombinant human growth hormone at 0.045-0.05 mg/kg/day has demonstrated safety and efficacy 1
• Growth hormone therapy must be administered as daily subcutaneous injections, with evening administration preferred to mimic physiological secretion patterns 1
• Growth hormone therapy should be discontinued when epiphyseal growth plates close, as no further height increase is possible after this point 1

Conclusion

• Ipamorelin and CJC-1295 are not approved for height enhancement, and no safe or effective dosage can be recommended 2, 5, 3
• Individuals concerned about height should consult with an endocrinologist for proper evaluation and evidence-based treatment options 2